November7 , 2026

    China grants zero duty to Indian pharma as US blocks imports with 100% tariff

    Related

    flydubai Launches Dedicated Freighter Service from Kochi to Dubai, Boosting Air Cargo Connectivity

    Cochin International Airport Limited (CIAL) has marked another significant...

    CEVA Logistics Opens 17,000-Sqm Pharmaceutical Logistics Facility in France

    CEVA Logistics has inaugurated a 17,000-sqm pharmaceutical logistics facility...

    OOCL to Launch New Far East–Chennai Service Connecting Malaysia and India

    Orient Overseas Container Line (OOCL) is set to launch...

    Visakhapatnam Port Berths Panamax Vessel at Inner Harbour for Export Alumina Loading for First Time

    Visakhapatnam Port Authority (VPA) has achieved a significant operational...

    VOC Port Records 50.63% Growth in Iron and Steel Cargo Handling

    V.O. Chidambaranar Port Authority (VOCPA) has recorded an impressive...

    Share

    In a major development, China has slashed the 30 percent import duty on Indian pharmaceutical products to zero. This landmark step will allow Indian drug manufacturers to export medicines to China without paying any customs duty. Experts say this decision could boost Indian pharma exports by billions of dollars in the coming years.

    Timing important as US raises tariffs

    The announcement comes just after US President Donald Trump imposed a 100 percent tariff on pharma imports, a move that could hurt India’s large drug-exporting industry. With the US market becoming costlier, China’s decision offers Indian companies an alternative market with strong demand for affordable medicines.

    Why it matters for India

    India is known as the ‘pharmacy of the world,’ supplying affordable generic drugs and vaccines across the globe. The Chinese market, with its huge population and growing healthcare needs, has long been difficult for Indian exporters due to high duties. Now, with a zero percent duty, Indian companies will have a level playing field and better access to one of the world’s largest healthcare markets.

    Experts see big opportunity

    Trade analysts believe this move will help balance India-China trade relations, which are often tilted in Beijing’s favour. Pharma industry leaders also expect this change to create thousands of jobs in India, boost revenues, and strengthen India’s position in global healthcare supply chains.